endocrine

Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…

1 month ago

MannKind to Highlight Data from Recent Pediatric and Adult Studiesof Inhaled Insulin (Afrezza) at American Diabetes Associations85th Scientific Sessions in Chicago, June 20-23

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the…

8 months ago